Medical Practice Sales: What to Know About Earnouts

Earnouts sit in an awkward place in medical practice sales. They can bridge a valuation gap, keep a deal moving, and help a buyer feel less exposed. They can also create years of friction after the closing dinner is over and the press release is forgotten.

That tension matters because a medical practice is not a widget factory. Revenue depends on patient retention, referral relationships, payer mix, physician productivity, staffing stability, scheduling discipline, compliance, and local reputation. When a buyer and seller disagree about value, they are often disagreeing about the future of those moving parts. An earnout is the tool they use to turn that disagreement into a contract.

I have seen earnouts work well when both sides treated them as a narrow, carefully drafted risk-sharing mechanism. I have also seen them unravel because one side assumed the business would run exactly as it had before, while the other side planned to integrate operations immediately. In healthcare, those assumptions collide fast.

If you are thinking about medical practice sales, the right question is not whether earnouts are good or bad. The right question is whether the proposed earnout actually fits the economics and operating reality of the practice being sold.

What an earnout really is

At its core, an earnout is contingent purchase price. The seller receives part of the price at closing and part later if the practice hits agreed performance targets. That sounds simple. It rarely stays simple.

In a typical transaction, the buyer may pay a base amount up front, then agree to additional payments over one to three years if the practice reaches certain benchmarks. Those benchmarks might be tied to collections, EBITDA, provider retention, patient visit volume, or a combination. In physician deals, especially when the selling doctor will keep practicing after closing, the earnout often becomes a proxy for future performance.

That is where the legal and financial drafting matters. A buyer may describe the earnout as a way to reward continued success. A seller may view it as deferred value they fully expect to receive. Those are not the same thing. If the buyer controls operations after closing, the buyer often controls many of the levers that determine whether the seller gets paid.

That imbalance is not always unfair. Sometimes the buyer is taking real risk. A specialty group buying a smaller practice may need to invest in billing, IT, compliance, and recruiting immediately. If the practice underperforms after integration, the buyer may argue that it should not have to pay the full premium. But if the buyer is also free to change staffing models, alter compensation, redirect referrals, close locations, or shift procedures to another entity, then the earnout can become a target the seller no longer controls.

Why earnouts show up so often in healthcare deals

Medical practices are notoriously difficult to value with precision. Historical financials tell only part of the story. A practice may have strong collections but weak documentation. It may have a loyal patient panel but a physician owner who plans to slow down. It may look highly profitable because physician compensation was below market, or look less profitable because the owner ran personal expenses through the business. In many cases, both sides can make reasonable arguments for very different valuations.

Earnouts show up when those arguments are hard to close. A buyer might say, “I believe in the upside, but I will pay for it only if it materializes.” A seller might respond, “If you are right about your platform and resources, then the practice should hit those targets and I should be compensated for the value I built.”

That dynamic is common in medical practice sales involving:

Practice founders nearing retirement who want to monetize goodwill but remain clinically active for a transition period.

Platform acquisitions by private equity backed groups that expect growth but do not want to overpay for projected synergies.

Specialty practices where revenue concentration depends heavily on one or two physicians.

Practices facing reimbursement uncertainty, such as a pending payer renegotiation or coding cleanup.

De novo or recently expanded offices with results that have not yet stabilized.

In each of those settings, the future matters more than the trailing twelve months. The earnout is meant to solve that problem. Sometimes it does. Often it simply relocates the disagreement from the purchase price discussion to the post-closing period.

The metrics are everything

The success or failure of an earnout usually comes down to the metric. Not the headline number in the letter of intent, but the exact defined term buried pages later in the purchase agreement.

A seller may believe the earnout is based on revenue growth. The agreement may actually define the target as net collections, excluding certain payers, measured after refunds, bad debt write-offs, and changes in billing policy. A buyer may think the target is straightforward EBITDA. The seller may later discover that new centralized management fees, corporate overhead allocations, and one-time integration costs have reduced that EBITDA enough to wipe out the payment.

In healthcare, net collections can be a cleaner metric than EBITDA in some situations, especially if the seller is staying on as a producing physician and the buyer will control overhead. Even then, the details matter. Are collections measured on a cash basis or accrual basis? Are old receivables included? How are pre-closing accounts handled? What happens if payer reimbursement timing shifts? If a major insurer changes adjudication practices in the middle of the earnout period, the result can distort the calculation without saying much about actual practice performance.

Work RVUs can also be useful, particularly where physician effort is the key variable. That said, RVUs can be gamed or influenced by coding changes, case mix, or the reassignment of procedures. Patient encounters may look objective but can become meaningless if appointment templates, staffing, telehealth protocols, or service lines change. EBITDA sounds sophisticated, but it is often the most litigated metric because post-closing cost allocations are easy to manipulate, whether intentionally or not.

I have seen one particularly avoidable dispute where the seller believed the earnout target would be measured using “normal accounting practices.” The buyer later standardized revenue recognition across its platform and moved billing support fees into the local P&L. Both actions were defensible from an accounting and management standpoint. Both reduced the apparent performance of the acquired practice. The contract language was vague enough that neither side felt clearly wrong, which is exactly the kind of ambiguity that leads to expensive arguments.

Control after closing is the hidden issue

Most earnout fights are not really about math. They are about control.

Once the sale closes, the buyer typically owns the assets or equity and has the authority to run the business. That authority may include staffing decisions, scheduling, marketing, EHR conversion, billing vendor changes, compensation design, and capital spending. Every one of those choices can affect the earnout.

Imagine a dermatology practice sold into a larger platform. The seller’s earnout is based on collections over the next twenty-four months. Six months after closing, the buyer changes the practice management system, and claim submission slows for two billing cycles. Then a key medical assistant leaves and is not replaced quickly, reducing physician throughput. Later, the buyer decides to consolidate call center functions, and no-show rates rise because local scheduling relationships disappear. Was the practice underperforming? In one sense, yes. Did the seller cause that underperformance? Not necessarily.

This is why sellers should focus as much on operational covenants as on the earnout formula. If a buyer wants contingent value based on future performance, the seller needs some protection against business decisions that materially reduce the chance of hitting the target. That does not mean the seller gets veto power over operations. It does mean the agreement should address the obvious pressure points.

At a minimum, the parties should discuss whether the buyer must operate the practice in good faith and not with the primary purpose of avoiding the earnout. Better still, they should address concrete issues such as maintaining the location for a set period, providing commercially reasonable staffing, preserving certain service lines, not diverting physicians or referrals away from the acquired practice, and using consistent accounting methods. General good faith language helps. Specific covenants help more.

When earnouts make sense

Earnouts are not inherently problematic. In the right deal, they are practical and fair.

They tend to work best when the selling physician will remain active, the revenue engine is relatively measurable, and the buyer has no immediate plan to radically restructure the practice. They also work better when the earnout period is short. A one-year measurement period often produces fewer disputes than a three-year period because there are fewer moving variables, less organizational drift, and a clearer connection between the seller’s efforts and the outcome.

A reasonable earnout can also be useful when both sides acknowledge genuine uncertainty. Consider a multi-site primary care practice that recently added two physicians whose patient panels are still ramping. The seller argues those hires should increase value. The buyer counters that physician recruiting does not guarantee retention or productivity. An earnout tied to actual realized collections from those providers over the next twelve to eighteen months may be a sensible compromise.

The same can be true when a practice has unusual concentration. Suppose forty percent of collections come from one surgeon who has signed a new employment agreement but has not yet demonstrated post-sale stability. The buyer may hesitate to pay full freight at closing. An earnout based on that surgeon’s continued production and retention can align the price with reality.

When sellers should be cautious

The more control shifts to the buyer, the more carefully a seller should approach an earnout. This is especially true in platform acquisitions where integration is part of the buyer’s strategy. If the practice will be folded into a broader network, rebranded, migrated to a new EHR, and managed under centralized billing and finance teams, then post-closing results may reflect the buyer’s system as much as the seller’s legacy practice.

Sellers should also be cautious when a large portion of the total consideration is contingent. A modest earnout can be a useful bridge. An outsized earnout can become a way for a buyer to advertise a headline purchase price it never really expects to pay.

The tax treatment and payment timing deserve attention too. Depending on structure, contingent payments may be treated differently from the closing payment, and the seller should review this with tax counsel. Cash flow timing matters in practical terms as well. A physician planning retirement may prefer a lower fixed price with certainty over a higher theoretical price spread across several years of performance conditions.

There is also a personal dimension. After many years of ownership, some physicians are emotionally tied to the practice they built. An earnout can keep them financially tied to post-closing performance while stripping away much of their decision-making authority. For some people, that is manageable. For others, it is a recipe for frustration.

The provisions that deserve real negotiation

Most attention goes to the target number. That is a mistake. The surrounding provisions often matter more.

Here are the terms I would read with particular care in any earnout tied to medical practice sales:

1. The exact metric and how it is calculated, including accounting conventions, exclusions, payer treatment, and treatment of pre-closing receivables.
2. Operational control terms, including whether the buyer can materially change staffing, locations, service lines, referral routing, or physician schedules during the earnout period.
3. Reporting and access rights, so the seller can review monthly performance data and understand whether the practice is on track.
4. Dispute procedures, including timing for objections, document access, and whether a neutral accountant will resolve calculation disagreements.
5. Acceleration or protection events, such as what happens if the buyer sells the practice again, terminates the seller without cause, or materially breaches operating covenants.

None of those points is glamorous. All of them matter. I have watched parties spend weeks arguing over a half-turn of EBITDA in valuation while giving barely an hour to the actual earnout mechanics. That is backwards.

A realistic example

Take a hypothetical ophthalmology practice with three physicians, $4.5 million in annual collections, and strong local referral relationships. The founding physician is selling to a regional platform but plans to keep practicing for two years. The platform offers $3.2 million at closing plus up to $1 million in earnout payments over two years.

On the surface, that may sound attractive. The founder focuses on the $4.2 million total. But the question is how the $1 million is earned.

If the earnout is based on EBITDA, and the buyer will impose a management fee, switch vendors, and allocate centralized administrative costs, the seller may have little visibility into whether the targets are achievable. If instead the earnout is tied to the founder’s personal collections and retention, with clear definitions and a commitment not to materially reduce clinic time, it starts to look more workable.

Now add a wrinkle. Six months after closing, one associate leaves unexpectedly. The buyer decides not to replace that doctor right away because the wider platform has recruiting issues. The remaining physicians become overbooked, staff burnout rises, surgery block utilization drops, and collections flatten. Was that a failure of the founder’s legacy practice? Probably not. Yet without careful drafting, the earnout may shrink anyway.

This is why experienced advisors often push for either narrower, physician-specific earnout metrics or meaningful protections around staffing and operations. Broad business performance targets can sound elegant but often allocate too much post-closing risk to the seller.

Alternatives to a classic earnout

Sometimes the better answer is not a better earnout, but less earnout.

If the valuation gap is modest, the parties may solve it through a seller note, which gives the seller more certainty than a pure contingent payment, though it introduces credit risk. In other situations, an employment agreement with performance bonuses can address future productivity more cleanly than embedding everything in the purchase price. A holdback tied to a specific issue, such as a pending payer recoupment or compliance matter, may be more appropriate than a broad operational earnout.

Another approach is tiered pricing at closing based on objective facts known before signing. For example, if the concern is whether a new physician will actually start on time or whether a lease renewal will be secured, those milestones may be better handled through conditional closing payments rather than a two-year earnout.

None of these options is automatically superior. The right structure depends on what uncertainty the parties are really trying to address. If the uncertainty is future physician productivity, then an earnout may fit. If the uncertainty is balance sheet cleanup, receivables collectability, or a contract renewal, there may be cleaner tools.

How buyers should think about fairness

Buyers sometimes treat earnouts as simple downside protection. That view is incomplete. A poorly designed earnout can damage retention, undermine trust, and sour the physician relationship that justified the acquisition in the first place.

In healthcare deals, the seller often remains a key clinician, referral source, or local leader. If that person believes the earnout is illusory, motivation changes. Cooperation on integration drops. Recruiting support weakens. Cultural alignment suffers. Even from a purely economic standpoint, a fair earnout is often better business than an aggressive one.

A buyer also gains credibility in the market by paying what it promises. In communities where physicians talk to one another, reputation travels quickly. If several local doctors conclude that a platform uses earnouts mainly to reduce the real purchase price after closing, future deal flow becomes harder.

Practical questions to ask before agreeing

Before either side signs, the deal team should be able to answer a handful of practical questions in plain English. If the answers are fuzzy, the drafting probably is too.

Ask these five:

1. What specific business risk is the earnout meant to solve?
2. Who actually controls the drivers of the earnout after closing?
3. Could the metric change materially because of integration choices rather than true performance?
4. How quickly will the seller know whether targets are being met or missed?
5. If the relationship becomes strained, does the agreement provide a workable path to resolve disputes?

These questions sound basic. They expose most of the real issues.

The lawyer, accountant, and healthcare advisor all matter here

Earnouts are one of those areas where interdisciplinary advice pays for itself. Transaction counsel can draft the legal protections, but healthcare-specific accounting input is often what reveals the practical problems. A formula that looks sensible in a draft may become unstable once someone maps it against payer timing, coding practices, physician compensation methodology, and platform cost allocation.

Industry knowledge matters too. A pediatric practice, an orthopedic group, and a med spa platform all have different operating rhythms and revenue drivers. The best earnout structure in one setting may be the wrong one in another. Specialty-specific judgment usually beats generic deal language.

That is especially true in medical practice sales, where regulatory and operational constraints can shape the economics in subtle ways. Even routine decisions about scheduling, provider mix, ancillary services, and supervision can have financial effects that spill into https://elliottgyba942.brightsora.com/posts/why-confidentiality-matters-in-medical-practice-sales the earnout calculation.

The bottom line for physician sellers

If you are selling your practice, do not evaluate an earnout by its maximum dollar amount alone. Focus on how likely it is to be paid, what has to happen operationally for that to occur, and whether you will have enough visibility and protection once the buyer takes over.

A strong earnout is concrete, measurable, relatively short, and tied to variables that the seller can influence or that the buyer cannot easily distort. A weak earnout is vague, heavily dependent on buyer-controlled accounting or integration choices, and large enough to make the headline valuation sound better than the guaranteed economics.

For buyers, the same principle applies from the other direction. If the earnout is intended to align incentives, design it so a reasonable seller can actually understand it, monitor it, and believe in it. If the structure depends on broad discretion that can move the goalposts after closing, the dispute is already embedded in the deal.

Earnouts are not a shortcut around valuation uncertainty. They are a way of allocating it. In medical practice sales, that allocation needs to reflect how healthcare businesses really operate, not just how a spreadsheet models them. When the parties respect that reality, an earnout can close a difficult deal. When they ignore it, the most contentious part of the transaction starts after the documents are signed.

Aesthetic Brokers
Address: 800 Silverado St #301A, La Jolla, CA 92037
Phone number: +16197420310

FAQ About Medical Practice Sales

How much do doctor practices sell for?

The sale price of a doctor's practice varies wildly by size and specialty, but most independent, single-location practices sell for a median price of $450,000 to $550,000. However, larger, multi-provider practices or highly specialized groups routinely sell for millions.

How long does it take to sell a medical practice?

Selling a medical practice typically takes 6 to 12 months from the initial preparation to the final closing, though complex transactions or unorganized financials can stretch the timeline to 12 to 18 months.

How do you value a medical practice for sale?

Valuing a medical practice for sale involves analyzing financial performance, adjusting earnings for a new owner, and applying standard valuation methods like the income, market, or asset approach. Most practices sell for a multiple of adjusted earnings or a percentage of annual revenue, guided by specialized industry standards.